← All trials
NCT04340128
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2007
- Primary completion
- Oct 31, 2007
- Completion date
- Dec 31, 2007
- First posted
- Apr 9, 2020
- Last posted
- Apr 9, 2020
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TehranLead sponsor
- University of TehranStudy director
- University of TehranOverall official - principal investigator
- Mashhad University of Medical SciencesStudy chair
- Kerman University of Medical SciencesStudy chair
- Kerman University of Medical SciencesCollaborator
- Mashad University of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.